These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15668185)

  • 1. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry.
    Labiós M; Martínez M; Gabriel F; Guiral V; Martínez E; Aznar J
    Thromb Res; 2005; 115(4):263-70. PubMed ID: 15668185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
    Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
    Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients.
    Puccetti L; Sawamura T; Pasqui AL; Pastorelli M; Auteri A; Bruni F
    Eur J Clin Invest; 2005 Jan; 35(1):47-51. PubMed ID: 15638819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
    Tetik S; Ak K; Isbir S; Eksioglu-Demiralp E; Arsan S; Iqbal O; Yardimci T
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):189-98. PubMed ID: 19703819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
    Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
    Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometric assay of platelet glycoprotein receptor numbers in hypercholesterolemia.
    Ozsavci D; Yardimci T; Demirel GY; Demiralp E; Uras F; Onder E
    Platelets; 2002 Jun; 13(4):223-9. PubMed ID: 12189024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
    Di Nisio M; Di Febbo C; Moretta V; Guglielmi MD; Stuppia L; Cuccurullo F; Porreca E
    Thromb Haemost; 2007 Sep; 98(3):642-6. PubMed ID: 17849054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased superoxide anion production by platelets in hypercholesterolemic patients.
    Sanguigni V; Pignatelli P; Caccese D; Pulcinelli FM; Lenti L; Magnaterra R; Martini F; Lauro R; Violi F
    Thromb Haemost; 2002 May; 87(5):796-801. PubMed ID: 12038779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
    Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
    Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients.
    Chan LW; Luo XP; Ni HC; Shi HM; Liu L; Wen ZC; Gu XY; Qiao J; Li J
    Braz J Med Biol Res; 2015 Feb; 48(2):167-73. PubMed ID: 25466164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects.
    Bruni F; Pasqui AL; Pastorelli M; Bova G; Di Renzo M; Cercigani M; Leo A; Auteri A; Puccetti L
    Int J Cardiol; 2004 Jun; 95(2-3):269-74. PubMed ID: 15193831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients.
    Luzak B; Boncler M; Rywaniak J; Wilk R; Stanczyk L; Czyz M; Rysz J; Watala C
    Eur J Pharmacol; 2011 May; 658(2-3):91-7. PubMed ID: 21371451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI.
    Yonemura A; Momiyama Y; Fayad ZA; Ayaori M; Ohmori R; Kihara T; Tanaka N; Nakaya K; Ogura M; Taniguchi H; Kusuhara M; Nagata M; Nakamura H; Tamai S; Ohsuzu F
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):222-8. PubMed ID: 19242355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    Lloret R; Ycas J; Stein M; Haffner S;
    Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.